Bone Therapeutics Reports Full Year 2015 Results Read more about Bone Therapeutics Reports Full Year 2015 Results
Bone Therapeutics announces the publication of its Annual Report 2015 Read more about Bone Therapeutics announces the publication of its Annual Report 2015
The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available Read more about The preliminary documents for the Annual General Shareholder Meeting on 26 May 2016 have been made available
Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study Read more about Bone Therapeutics completes recruitment of its ALLOB®Phase IIA spinal fusion study
Bone Therapeutics Provides Business Update for the First Quarter of 2016 Read more about Bone Therapeutics Provides Business Update for the First Quarter of 2016
Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial Read more about Bone Therapeutics announces further positive efficacy in ALLOB® Phase I/IIA delayed-union fracture trial
Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development Read more about Bone Therapeutics to enhance value of its severe osteoporosis program by transitioning to allogeneic development
Bone Therapeutics celebrates ten years of innovation in bone cell therapy Read more about Bone Therapeutics celebrates ten years of innovation in bone cell therapy
Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR Read more about Bone Therapeutics demonstrates superiority of PREOB® in Phase IIB osteonecrosis study presented at EULAR
Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016 Read more about Bone Therapeutics Half Year 2016 Results to be announced on 30 August 2016